This large prospective intraindividual comparison of [ 18 F]PSMA-1007 PET/CT vs [ 68 Ga]Ga-PSMA-11 PET/CT has demonstrated overall high concordance (92%) for TNM stage in the context of prostate cancer primary staging, biochemical recurrence and evaluation of patients with metastatic disease. Reduced [ 18 F]PSMA-1007 urinary radiotracer excretion improves characterisation of disease adjacent the bladder (prostate or prostate bed following de nitive treatment, including local invasion) and ureters (peri-ureteric nodes) compared to [ 68 Ga]Ga-PSMA-11. [ 18 F]PSMA-1007 demonstrates signi cantly higher uptake within involved nodes and bone metastases, and physiologic tissues including liver, spleen, neural ganglia, bone marrow and benign nodes. Inexperienced reporters of [ 18 F]PSMA-1007 PET should understand that hepatic uptake may obscure metastases within the liver or adjacent adrenal gland, and that [ 18 F]PSMA-1007 is associated with more equivocal bone lesions. Both tracers are acceptable for imaging of prostate cancer, with factors in uencing choice including availability (local generator production of [ 68 Ga]Ga-PSMA-11 vs external cyclotron supply [ 18 F]PSMA-1007), preference for improved characterisation of disease in the prostate and pelvic nodes (favouring [ 18 F]PSMA-1007) versus likelihood of visceral metastasis (favouring [ 68 Ga]Ga-PSMA-11) and the experience of reporting specialists to exclude benign patterns of uptake, particularly neural ganglia and equivocal bone lesions.

No abstract

A direct seedless method for the continuous synthesis of gold nanorods has been developed using a sequential rotating tube-narrow channel processing microfluidic configuration, with the stock feed solutions (HAuCl(4)/CTAB/acetylacetone and AgNO(3)/CTAB/carbonate buffer) being stable for weeks.

Purpose: [ 18 F]PSMA-1007 offers advantages of low urinary tracer excretion and improved resolution for imaging prostate cancer. However, non-speci c bone lesions (NSBLs), de ned as mild to moderate focal bone uptake without a typical morphological correlate on CT, are a common nding on [ 18 F]PSMA-1007 PET/CT. The purpose of this study was to investigate the clinical outcomes of patients with [ 18 F]PSMA-1007 avid NSBLs, to determine whether patients with NSBLs represent a higher risk clinical cohort, and to determine whether SUVmax can be used as a classi er of bone metastasis.Methods: A retrospective audit of 214 men with prostate cancer was performed to investigate the clinical outcomes of [ 18 F]PSMA-1007 avid NSBLs according to de ned criteria. We also compared the serum PSA, Gleason score and uptake time of patients with [ 18 F]PSMA-1007 avid NSBLs to patients without [ 18 F]PSMA-1007 avid bone lesions. Finally, we assessed whether SUVmax is a good classi er of bone metastases using ROC curve analysis.Results: No [ 18 F]PSMA-1007 avid NSBLs met criteria for a likely malignant or de nitely malignant lesion after a median 15.8-month follow-up interval (11.9% de nitely benign, 50.3% likely benign, and 37.7% equivocal). There were no statistically signi cant differences in serum PSA, Gleason score and uptake time between patients with [ 18 F]PSMA-1007 avid NSBLs and those without [ 18 F]PSMA-1007 avid bone lesions. All NSBLs with adequate follow-up had SUVmax ≤11.1. When comparing NSBLs to de nite prostate cancer bone metastases, the highest SUVmax value recorded was a good classi er of bone metastasis, and an SUVmax cut-point of ≥7.2 maximised the Youden's index.Conclusion: [ 18 F]PSMA-1007 avid NSBLs rarely represent prostate cancer bone metastases. When identi ed in the absence of de nite metastatic disease elsewhere, it is appropriate to classify those with SUVmax <7.2 as likely benign. NSBLs with SUVmax 7.2-11.1 may be classi ed as equivocal or metastatic, with patient clinical risk factors, scan appearance, and potential management implications used to guide interpretation.